CD274 and glioblastoma: Similarly, in a phase II trial of autologous heat shock protein peptide vaccine combined with standard therapy in newly diagnosed glioblastoma, a median overall survival in patients with low PD-L1 expression on myeloid cells was 44.7 versus 18.0 months for patients with high PD-L1 expression (234).